These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21434470)

  • 1. [Ladasten in the management of non-motor symptoms of Parkinson's disease].
    Sarycheva TN; Rybak VA; Kurushina OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(1):85-7. PubMed ID: 21434470
    [No Abstract]   [Full Text] [Related]  

  • 2. [The possibilities of using himantane in the treatment of Parkinson's disease].
    Katunina EA; Petrukhova AV; Avakian GN; Val'dman EA; Nerobkova LN; Voronina TA; Saiadian KhS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(6):24-7. PubMed ID: 18577930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pilot clinical trial of ladasten].
    Siuniakov SA; Grishin SA; Teleshova ES; Neznamov GG; Seredenin SB
    Eksp Klin Farmakol; 2006; 69(4):10-5. PubMed ID: 16995430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International guide to drugs for Parkinson's disease.
    Oertel WH; Dodel RC
    Mov Disord; 1995 Mar; 10(2):121-31. PubMed ID: 7753054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten].
    Voznesenskaia TG; Fokina NM; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):17-26. PubMed ID: 21322821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].
    Reutova MA; Siuniakov SA; Siuniakov TS; Dorofeeva OA; Mametova LÉ; Neznamov GG
    Eksp Klin Farmakol; 2011; 74(11):6-13. PubMed ID: 22288153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.
    Mikhaylova M; Vakhitova JV; Yamidanov RS; Salimgareeva MKh; Seredenin SB; Behnisch T
    Neuropharmacology; 2007 Oct; 53(5):601-8. PubMed ID: 17854844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prospects for using ladasten preparations in patients with irritable bowel syndrome].
    Uspenskiĭ IuP; Fominykh IuA
    Eksp Klin Gastroenterol; 2010; (10):75-9. PubMed ID: 21434378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)].
    Neznamov GG; Siuniakov SA; Teleshova SE; Chumakov DV; Reutova MA; Siuniakov TS; Mametova LE; Dorofeeva OA; Grishin SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):20-6. PubMed ID: 19491814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gabapentin and motor fluctuations in Parkinson's disease.
    Chaná P; de Marinis A; Barrientos N
    Mov Disord; 1997 Jul; 12(4):608. PubMed ID: 9251083
    [No Abstract]   [Full Text] [Related]  

  • 11. Off and on state assessment of swallowing function in Parkinson's disease.
    Warnecke T; Hamacher C; Oelenberg S; Dziewas R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):1033-4. PubMed ID: 24997546
    [No Abstract]   [Full Text] [Related]  

  • 12. [Depressive symptoms and motor condition in Parkinson's disease patients].
    Stella F; Bucken-Gobbi LT; Gobbi S; Sant'Ana-Simões C
    Rev Neurol; 2007 Nov 16-30; 45(10):594-8. PubMed ID: 18008264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case studies in the advancement of Parkinson's disease.
    Frei K; Truong DD; Wolters E
    CNS Spectr; 2008 Dec; 13(12 Suppl 18):1-6. PubMed ID: 19179948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].
    Neznamov GG; Bochkarev VK; Reutova MA; Shabanova AA; Siuniakov SA
    Eksp Klin Farmakol; 2012; 75(5):7-13. PubMed ID: 22834121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
    Levin OS; Ivanov AK; Shindriaeva NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(1):38-42. PubMed ID: 21350410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-dopaminergic treatments for Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2010 Oct; 166(10):811-5. PubMed ID: 20832090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of ladasten effect in neurasthenia patients with various EEG parameters].
    Neznamov GG; Bochkarev VK; Siuniakov SA; Grishin SA
    Eksp Klin Farmakol; 2008; 71(4):18-25. PubMed ID: 18819436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern therapy of Parkinson's disease.
    Ransmayr G; Künig G; Gerstenbrand F
    J Neural Transm Suppl; 1992; 38():129-40. PubMed ID: 1491245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing therapy in patients with disabling Parkinson's disease symptoms.
    Calne DB; Duvoisin RC; Koller WC
    Neurology; 1994 Mar; 44(3 Suppl 1):S8-11. PubMed ID: 8121579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.